Recent in vivo studies from others as well as the investigators group demonstrated that volatile anesthetics immunomodulate sepsis and improve outcome. Also, several clinical trials have convincingly shown that application of a volatile anesthetic provides protection in patients undergoing major surgery.
Patients with sepsis are intubated and ventilated and therefore need sedation. So far, most ICU centers use intravenously applied sedatives in these patients. In the proposed study, we will switch sedation from an intravenous to a volatile anesthetic for a short period of time to explore if sepsis markers improve within the following 120 hours upon sevoflurane conditioning.

Start Date01 Jan 2025

Sponsor / Collaborator

University of Zurich

[+2]

NCT06457958 / Not yet recruitingPhase 4IIT

The Effect of Sevoflurane and Desflurane Anesthetic Agents Used in Elective Cholecystectomy Surgery on Heme Oxygenase-1 mRNA Expression and Heme Oxygenase-1 Protein Levels: A Comparative Prospective Study

General anesthesia is routinely administered to patients who undergo elective cholecystectomy. The most commonly used inhalation agents during general anesthesia are sevoflurane and desflurane. Participants who will undergo elective cholecystectomy surgery and meet the eligibility criteria will be randomized. Participants will be divided into two groups. One group will receive sevoflurane, and the other group will receive desflurane. Preoperative and postoperative blood samples will be taken from the participants. After the sample collection process is completed, the ELISA method will be used for measuring blood heme oxygenase-1 protein levels, and the PCR technique will be used for measuring blood heme oxygenase-1 mRNA gene expression. The increase in amounts between the two groups will be compared. This study aims to demonstrate the effects of the most commonly used inhalation agents on the levels of heme oxygenase-1 enzyme, which has been shown to be an important enzyme in cellular protection mechanisms, as well as on mRNA gene expression, and to determine which agent may be more effective in preventing cellular damage at the molecular level.

Start Date01 Aug 2024

Sponsor / Collaborator-

NCT05680545 / Not yet recruitingNot Applicable

Volatile Anesthetic Pharmacokinetics During Extracorporeal Membrane

The goal of this study is to design a pilot trial evaluating the safety, feasibility, pharmacokinetic modeling, and physiological effects of a volatile anesthetic, sevoflurane, directly administered in extracorporeal membrane oxygenation machines.

Start Date01 Jul 2024

Sponsor / Collaborator

University Health Network

[+1]

100 Clinical Results associated with Sevoflurane

100 Translational Medicine associated with Sevoflurane

100 Patents (Medical) associated with Sevoflurane

10,526

Literatures (Medical) associated with Sevoflurane

01 May 2024·Journal of clinical anesthesia

Differential effects of sevoflurane and desflurane on frontal intraoperative electroencephalogram dynamics associated with postoperative delirium

Article

Author: Park, Sujung ; Kim, Jeongmin ; Kim, Keung Nyun ; Koo, Bon-Nyeo ; Shin, Dong Ah ; Kim, Yeon-Su ; Kuh, Sung Uk ; Ha, Yoon ; Kim, Seong-Eun ; Yi, Seong ; Lee, Chang Kyu

STUDY OBJECTIVE:

Intraoperative electroencephalogram (EEG) patterns associated with postoperative delirium (POD) development have been studied, but the differences in EEG recordings between sevoflurane- and desflurane-induced anesthesia have not been clarified. We aimed to distinguish the EEG characteristics of sevoflurane and desflurane in relation to POD development.

DESIGN AND PATIENTS:

We collected frontal four-channel EEG data during the maintenance of anesthesia from 148 elderly patients who received sevoflurane (n = 77) or desflurane (n = 71); 30 patients were diagnosed with delirium postoperatively. The patients were divided into four subgroups based on anesthetics and delirium status: sevoflurane delirium (n = 17), sevoflurane non-delirium (n = 60), desflurane delirium (n = 13), and desflurane non-delirium (n = 58). We compared spectral power, coherence, and pairwise phase consistency (PPC) between sevoflurane and desflurane, and between non-delirium and delirium groups for each anesthetic.

MAIN RESULTS:

In patients without POD, the sevoflurane non-delirium group exhibited higher EEG spectral power across 8.5-35 Hz (99.5% CI bootstrap analysis) and higher PPC from alpha to gamma bands (p < 0.005) compared to the desflurane non-delirium group. Conversely, in patients with POD, no significant EEG differences were observed between the sevoflurane and desflurane delirium groups. For the sevoflurane-induced patients, the sevoflurane delirium group had significantly lower power within 7.5-31.5 Hz (99.5% CI bootstrap analysis), reduced coherence over 8.9-23.8 Hz (99.5% CI bootstrap analysis), and lower PPC values in the alpha band (p < 0.005) compared with the sevoflurane non-delirium group. For the desflurane-induced patients, there were no significant differences in the EEG patterns between delirium and non-delirium groups.

CONCLUSIONS:

In normal patients without POD, sevoflurane demonstrates a higher power spectrum and prefrontal connectivity than desflurane. Furthermore, reduced frontal alpha power, coherence, and connectivity of intraoperative EEG could be associated with an increased risk of POD. These intraoperative EEG characteristics associated with POD are more noticeable in sevoflurane-induced anesthesia than in desflurane-induced anesthesia.

01 May 2024·Current drug delivery

Comparing Recovery from Desflurane and Sevoflurane in Patients with Different Body Fat Percentages: A Randomized Controlled Trial

Author: Cao, Silu ; Wang, Huijuan ; Tang, Lijun ; An, Guanghui

Introduction::

Increased body fat may influence the partition coefficients of inhaled anesthetics. We compared patient responses to desflurane and sevoflurane anesthesia, as measured by a quicker recovery and fewer complications, in patients with higher body fat percentages, not only obese people.

Methods::

This study included 120 patients. Participants were stratified into low or high body fat percentages groups using bioelectrical impedance analysis and were randomized 1:1 to receive desflurane or sevoflurane as an inhaled anesthetic, recorded as Low-Desflurane, Low-Sevoflurane, High- Desflurane, and High-Sevoflurane. Recovery time, Riker sedation–agitation scale scores, and complications were recorded over 1 hour in the post-anesthesia care unit.

Results::

A total of 106 patients were analyzed. There were no significant differences in the overall recovery time between the patient subgroups with higher and lower body fat percentages; in addition, there were no significant differences in the incidence of nausea, vomiting,dizziness, or headache (all p>0.05). However, the incidence of agitation emergence in the HighSevoflurane subgroup was significantly higher compared to the High-Desflurane subgroup (33.3% vs.7.41%; p = 0.043).

Conclusion::

In conclusion, for patients with a lower body fat percentage, both desflurane and sevoflurane can provide good and fast recovery; for patients with a higher body fat percentage,desflurane may provide better recovery with a lower incidence of agitation emergence compared to sevoflurane.

01 Apr 2024·Anaesthesia, critical care & pain medicine

Electroencephalographic density spectral array monitoring during propofol/sevoflurane coadministration in children, an exploratory observational study

Article

Author: Karaöz-Bulut, Gulhan ; Weber, Frank ; Krul, Stephan ; Raab, Hannah A C ; Stolker, Robert-Jan ; de Heer, Iris J

INTRODUCTION:

Propofol and sevoflurane have a long history in pediatric anesthesia. Combining both drugs at low dose levels offers new opportunities. However, monitoring the hypnotic effects of this drug combination in children is challenging, because the currently available processed EEG-based systems are insufficiently validated in young children and the co-administration of anesthetics. This study investigated electroencephalographic density spectral array monitoring during propofol/sevoflurane coadministration with fixed sevoflurane- and variable propofol dosages.

PATIENTS AND METHODS:

We analyzed the density spectral array pattern recorded during propofol/sevoflurane anesthesia in pediatric patients from birth to 11 years of age. Data from 78 patients were suitable for analysis. The primary outcome parameter of this study was the correlation between variable propofol dosages and the expression of the four electroencephalogram frequency bands β, α, θ, and δ. The main secondary outcome parameters were the intra-operative total EEG power and the prevalence of burst suppression.

RESULTS:

In patients above the age of 1 year, a dose-dependent correlation between the propofol dosage and the relative percentage of β (-12.2%, p < 0.001) and δ (5.1%, p < 0.001) was found. There was an age-dependent trend toward increasing mean EEG power, with the most significant increase in the first year of life. In 14.1% of our patients, at least one episode of burst suppression occurred.

CONCLUSION:

DSA-guided augmentation of propofol anesthesia with sevoflurane provides sufficient depth of anesthesia at doses usually considered sub-anesthetic in children, leading to less anesthetic drug exposure for the individual child.

News (Medical) associated with Sevoflurane

02 Apr 2024

·www.prnewswire.com

Mars Veterinary Health pilots industry-leading anaesthetic gas capture technology to reduce carbon emissions

World's leading provider of veterinary care will be first to introduce innovative in-clinic solution to support sustainability goals BIRMINGHAM, England, April 3, 2024 /PRNewswire/ -- Mars Veterinary Health, through its UK veterinary group Linnaeus and in partnership with Waltham Petcare Science Institute, today announced a first-of-its-kind partnership with SageTech Veterinary to pilot an innovative anaesthetic gas capture solution to help prevent harmful greenhouse gases from entering the atmosphere. During a typical anaesthetic procedure, less than five percent of the volatile anaesthetic agent delivered to a patient is absorbed and metabolised, leaving approximately 95 percent it to be exhaled. Continue Reading Mars Veterinary Health pilots industry-leading anaesthetic gas capture technology to reduce carbon emissions SageTech's trusted gas-capture technology—which is currently used in human healthcare—works by capturing the waste anaesthetic agent breathed out during an operation by safely adsorbing it into a specially developed reusable capture canister. These waste anaesthetic agents can then be extracted from the filter, avoiding current routes for disposal of volatile anaesthetic agents of incineration or release into the atmosphere. "As a leading provider of veterinary care, we have a responsibility to take climate action at scale and lead the way toward more sustainable practices," said Ellie West, RCVS and EBVS® European Specialist in Veterinary Anaesthesia and Analgesia, and Linnaeus Environmental Sustainability Lead. "Our innovative collaboration should help us take a significant step forward in our sustainability journey, aimed at contributing to a better future for the planet—and the people and pets who depend on it." A veterinary-industry first, Mars Veterinary Health's one-year pilot will start with 10 Linnaeus primary care and referral veterinary practices in the UK with the aim of reducing anaesthesia-related carbon emissions resulting from release or disposal of these agents and determining the efficiency of capture in its clinics, ultimately supporting its goal of reducing climate-change impacts. Mars Veterinary Health aims to use these learnings to explore the potential application of this technology across other parts of its business in the years to come. "At SageTech Veterinary, we are excited to share our developed technology and work alongside Mars Veterinary Health to significantly reduce the carbon footprint associated with the direct release of waste volatile anaesthetic agents to the environment," said Iain Menneer, CEO of SageTech Medical. "It has been wonderful to work with the Linnaeus and Waltham teams, and we are confident this pilot project will demonstrate to the veterinary profession how such collaborations can be a collective force for good." This industry-first pilot in sustainable veterinary care is consistent with Mars, Incorporated's Net Zero Roadmap, a detailed action plan for achieving net zero greenhouse gas emissions by 2050, as well as details on the company's progress and history of working on climate action. Details about Mars, Incorporated's wider sustainability—including climate—work can be found in its Sustainable in a Generation Scorecard. About Mars Veterinary Health Mars Veterinary Health is a global division of Mars Petcare dedicated to delivering high-quality pet healthcare to further its collective Purpose: A BETTER WORLD FOR PETS™. Mars Veterinary Health's 70,000 Associates across 3,000 global veterinary clinics put pets, people, and the planet first. The Mars Veterinary Health family includes Associates at AniCura, Banfield, BluePearl, Creature Comforts, Gentle Oak, Hillside, Linnaeus, Mount Pleasant, Tai Wai, VCA, VES, and VSH who demonstrate compassion and expertise while enabling 35 million pet visits each year. Learn more at marsveterinary.com. About Linnaeus Part of Mars Veterinary Health, Linnaeus is a highly respected community of more than 50 primary care and 17 referral veterinary practices based in the UK. Linnaeus employs over 6,000 pet-loving Associates with some of the country's finest vet and nursing teams who together are committed to excellence and delivering high-quality care to patients. Learn more at linnaeusgroup.co.uk. About Mars Science & Diagnostics Mars Science & Diagnostics is a division of Mars Petcare, a diverse business dedicated to one purpose: A BETTER WORLD FOR PETS™. Science & Diagnostics brings together the power of leading pet health science with expertise across diagnostics, data, and technology to improve outcomes in pet health. Antech, our global veterinary diagnostics business, spans in-house diagnostic laboratory instruments and consumables, including rapid assay diagnostic products and digital cytology services; local and cloud-based data services; practice information management software; reference laboratories; veterinary imaging and technology; education; and telemedicine with board-certified specialist support services. Our at-home diagnostics offering includes Wisdom Panel, the world's most accurate pet DNA test. For 60 years, our Waltham Petcare Science Institute has been advancing science to better understand pet health. About SageTech Veterinary The manufacture of virgin anaesthetic agents and their release as waste volatile gases is highly damaging to the environment and contributes significantly to the total carbon footprint of healthcare. SageTech Veterinary is part of SageTech Medical, a medical device and pharmaceutical company focused on the research, design, manufacture, and distribution of technologies for the capture and recycling of waste volatile anaesthetic agents in human and animal healthcare. Their unique circular economy solution safely captures volatile anaesthetic agents (sevoflurane, isoflurane, desflurane) through actively controlled adsorption onto a reusable capture canister. Learn more at sagetechveterinary.com. Photo - SOURCE Mars PetCare

12 Jan 2023

·www.medicalplasticsnews.com

Diamedica to showcase anaesthesia and respiratory solutions at Arab Health

UK manufacturer Diamedica will be showcasing how their portable systems can enable safe anaesthesia and respiratory support in limited resource settings at Arab Health 2023. Joining the ABHI UK Pavilion, the company will be showcasing its Glostavent DPA03 portable anaesthesia machine and the Diamedica Portable CPAP, a small, hands-free, neonatal CPAP device, designed to function in some of the world’s most challenging environments. Manufactured in the UK, the portable Glostavent DPA03 does not require electrical or battery power and is designed to function anywhere, from the field or working to an outreach hospital or rural clinic. Its two vaporisers make it suitable for use with Halothane, Isoflurane or Sevoflurane so users can maximise resources. Lightweight and assembled in two minutes, the system is contained in a tough Peli case, making it safe and easy to transport to help save lives. The system can be optionally supplied with a vital signs monitor, improving the safety and efficacy of anaesthesia provision to the patient. The portable system is designed to provide excellent economy of oxygen use, with just two litres per minute of oxygen providing the average patient with 50% FiO2. In low-resource settings, access to CPAP can be scarce. To meet this need, Diamedica have created the Diamedica Portable CPAP, a low cost, and portable CPAP device designed to support neonates and infants with respiratory distress syndrome. Manufactured with simplicity in mind, the system provides filtered room air through a patient cannula interface. It provides a compact and effective respiratory device for use in a range of settings including transport internally in the hospital or externally to another facility. The device can also be used when the number of patients in need of CPAP therapy exceeds the number of standalone CPAP machines available or when electricity or compressed gas supply is not readily available. Diamedica’s award-winning technology is already in use in more than 80 countries around the world. Charlotte Green, head of sales and marketing at Diamedica, said: “Arab Health sees thousands of industry players congregate in Dubai for four days of business and knowledge sharing, the perfect location to showcase our latest innovations. We look forward meeting key stakeholders and potential distributors to discuss our sustainable and innovative medical device solutions and demonstrate how our anaesthesia and respiratory solutions are specifically designed to perform to full capability in some of the most challenging environments around the world.” Diamedica’s product range extends from full hospital anaesthetic machines, oxygen concentrator driven CPAP, oxygen reservoir filling system, to portable anaesthesia and ventilation for field hospitals, outreach missions, conflict and humanitarian situations. All designed to bespoke specifications to suit low-resource settings. Recognised as an expert in the field, the company works hand-in-hand with in-country partners to provide training, education and distribution to equip their customers with the knowledge and resources they need. The Arab Health Exhibition & Congress is taking place from 30 January – 2 February 2023 at the Dubai Convention and Exhibition Centre. Throughout the exhibition, Diamedica will be located on the ABHI UK Pavilion – Stand H2.D14.

02 Dec 2022

·www.businesswire.com

Global Inhalation Anesthetics Market to Reach $1.5 Billion by 2027 at a CAGR of 3.7% - ResearchAndMarkets.com

DUBLIN--( BUSINESS WIRE )--The "Inhalation Anesthetics: Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. Global Inhalation Anesthetics Market to Reach $1.5 Billion by 2027 In the changed post COVID-19 business landscape, the global market for Inhalation Anesthetics estimated at US$1.2 Billion in the year 2020, is projected to reach a revised size of US$1.5 Billion by 2027, growing at a CAGR of 3.7% over the analysis period 2020-2027. Sevoflurane, one of the segments analyzed in the report, is projected to record a 3.6% CAGR and reach US$906.9 Million by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Desflurane segment is readjusted to a revised 4.3% CAGR for the next 7-year period. The U.S. Market is Estimated at $349 Million, While China is Forecast to Grow at 3.4% CAGR The Inhalation Anesthetics market in the U.S. is estimated at US$349 Million in the year 2020. China, the world's second largest economy, is forecast to reach a projected market size of US$273.6 Million by the year 2027 trailing a CAGR of 3.4% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3.5% and 3% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 3.6% CAGR. Nitrous Oxide Segment to Record 3.4% CAGR In the global Nitrous Oxide segment, USA, Canada, Japan, China and Europe will drive the 3.4% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$138 Million in the year 2020 will reach a projected size of US$175 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Select Competitors (Total 41 Featured) - 058 LatchGas Abbott Laboratories, Inc. AbbVie, Inc. Accutron Baxter International, Inc. Chester County Family Dentistry Discover Dental Eisai Co., Ltd. Fox Family Dentistry Fresenius Kabi AG Key Topics Covered: I. METHODOLOGY II. EXECUTIVE SUMMARY 1. MARKET OVERVIEW Influencer Market Insights World Market Trajectories Inhalation Anesthetics - Global Key Competitors Percentage Market Share in 2022 (E) Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E) Impact of Covid-19 and a Looming Global Recession 2. FOCUS ON SELECT PLAYERS 3. MARKET TRENDS & DRIVERS 4. GLOBAL MARKET PERSPECTIVE III. MARKET ANALYSIS IV. COMPETITION Companies Mentioned 058 LatchGas Abbott Laboratories, Inc. AbbVie, Inc. Accutron Baxter International, Inc. Chester County Family Dentistry Discover Dental Eisai Co., Ltd. Fox Family Dentistry Fresenius Kabi AG For more information about this report visit https://www.researchandmarkets.com/r/h9qiji

100 Deals associated with Sevoflurane

External Link

KEGG	Wiki	ATC	Drug Bank
D00547	Sevoflurane	N01AB08	DB01236

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Anesthesia	JP	Maruishi Pharmaceutical Co., Ltd.	20 Apr 1990

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04355962 (Pubmed)	Phase 3	COVID-19 IL-6	60	Sevoflurane sedation	ysndcrtqjs(hxdgmllrgt) = rbbslwpvyy kbcbrplroj (vwucsdpyew ) View more	Negative	27 Mar 2024
				Continuous intravenous sedation	ysndcrtqjs(hxdgmllrgt) = aoeeqdypfv kbcbrplroj (vwucsdpyew ) View more
NCT02662257 \| ChiCTR-IPR-15006209 (Pubmed)	Not Applicable	Delirium	1,228	Propofol-based anaesthesia	cgdxbvpqju(apfdmsceyv) = bzsaazircv jwmrxxvtud (ouzdzpzsrd )	Positive	01 Aug 2023
				Sevoflurane-based anaesthesia	cgdxbvpqju(apfdmsceyv) = bkjxbebohh jwmrxxvtud (ouzdzpzsrd )
NCT03553446 (Pubmed)	Not Applicable	Cerebral Palsy	23	Sevoflurane	zfcjoddfpr(mqukejwkhs) = mxjrkqjhvy igknwwqrqc (bwvqwwyeah, 1.62 - 1.90) View more	Positive	21 Oct 2022
NCT02489734 (CTgov)	Not Applicable	Emergence Delirium	109	Sevoflurane (Low Concentration (LC))	gaiytozbuh(kysxknapyp) = dpxrdqvjhe cfcpxiwode (muvtemzhpq, kozznqvdmm - vocovxeelm) View more	-	19 Aug 2021
				Sevoflurane (High Concentration (HC))	gaiytozbuh(kysxknapyp) = ftfxksonfz cfcpxiwode (muvtemzhpq, ejensjhady - rhuwhmvygh) View more
NCT02918877 (CTgov)	Phase 1/2	Oxygen radical damage \| Postoperative Complications \| Lung Injury	51	Sevoflurane (Inhaled Anesthesia)	nkevnmmcss(jdnraxexlw) = fcffktlzqo fvcwepaphq (bvysmzkpfg, ulbkynrpgl - brdnhmakos) View more	-	05 May 2021
				Propofol (Intravenous Anesthesia)	nkevnmmcss(jdnraxexlw) = rjvuqruvlp fvcwepaphq (bvysmzkpfg, hlsokwonmc - smpizmgvla) View more
NCT03498235 (Pubmed \| BMC Anesthesiol)	Early Phase 1	-	110	Propofol	rggvvumgba(dwbeuyahyj) = zvggstfrss qcpwuyleds (tfciztgdnj )	-	27 Jan 2021
				Sevoflurane	rggvvumgba(dwbeuyahyj) = zhjlazglbl qcpwuyleds (tfciztgdnj )
NCT03540030 (CTgov)	Phase 4	Opioid abuse \| Osteonecrosis \| Shoulder arthritis ... View more	86	opioids (Observational)	jbjbjervhp(juokgogmoe) = ubglzaqbdf elfpuvifei (evyxxhbgwb, zxlvzldfti - zglapggyyi) View more	-	12 Oct 2020
				regional block+acetaminophen+propofol+toradol+desflurane+sevoflurane+IV lidocaine+rocuronium+Celecoxib+vecuronium+Gabapentin (Non-Opioid Intervention)	jbjbjervhp(juokgogmoe) = nfoxfllzkd elfpuvifei (evyxxhbgwb, khwelegcuo - bpqbyftfuw) View more
NCT02038894 (CTgov)	Not Applicable	Eosinophilic Esophagitis	179	Intubated with Sevoflurane (IS) (Intubated With Sevoflurane (IS))	qhrjacrxqm(mwxaiputbk) = xzmsbzpgkh uevoqjjlpe (udxetspkla, zyisqyzkfu - ldbxedzrgg) View more	-	24 Sep 2020
				Intubated with Propofol (IP) (Intubated With Propofol (IP))	qhrjacrxqm(mwxaiputbk) = kuusabpwwb uevoqjjlpe (udxetspkla, btjrbeqsoe - hlydvonfzf) View more
NCT02664922 (CTgov)	Phase 4	Heart Diseases	35	Propofol (Sedation - Group 1)	ffdeuznepi(ltgczcpfjy) = duckfnfdnq pskkdpkqof (cxcuxglzjo, smylaqsryw - caofwcrnqb) View more	-	22 Sep 2020
				Propofol+ketamine (Sedation - Group 2)	ffdeuznepi(ltgczcpfjy) = iskzxjsgel pskkdpkqof (cxcuxglzjo, hmtaxupkzs - vlxfffvqoq) View more
ARVO2020	Not Applicable	-	-	Sevoflurane gas	pcwywobqpm(rvlmoaqkex) = mqyalanzlm agkhldeukg (darroxwmcr )	-	01 Jun 2020
				Propofol infusion	pcwywobqpm(rvlmoaqkex) = vtmzourrzr agkhldeukg (darroxwmcr )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis